CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer

OBJECTIVE: Olaparib (O), a polyADPribose polymerase (PARP) inhibitor, and cediranib (C), a VEGF receptor (VEGFR)1–3 inhibitor together had greater activity than O alone in women with recurrent platinum-sensitive ovarian cancer (OvCa). The objective of this study is to identify potential lead biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung-Min, Trepel, Jane B., Choyke, Peter, Cao, Liang, Sissung, Tristan, Houston, Nicole, Yu, Minshu, Figg, William D., Turkbey, Ismail Baris, Steinberg, Seth M., Lee, Min-Jung, Ivy, S. Percy, Liu, Joyce F., Matulonis, Ursula A., Kohn, Elise C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450585/
https://www.ncbi.nlm.nih.gov/pubmed/26082895
http://dx.doi.org/10.3389/fonc.2015.00123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450585/
https://www.ncbi.nlm.nih.gov/pubmed/26082895
http://dx.doi.org/10.3389/fonc.2015.00123

Ejemplares similares